Inherited risk factors for venous thromboembolism: implications for clinical practice.
Each year, thrombosis in the deep veins of the lower extremities occurs in 1 of every 1000 Americans (1). Although most cases of venous thrombosis are not fatal, death from pulmonary embolism can be expected in 1% to 2% of all patients, and as many as 25% of patients with deep venous thrombosis (DVT) will suffer the chronic effects of postthrombotic syndrome. Thus, identification of high-risk patients with genetic predispositions to thrombosis is an important clinical goal, particularly among individuals with recurrent DVT.
Ridker
Paul M
PM
Cardiovascular Division, Division of Preventive Medicine, Brigham and Women's Hospital, USA.
D020016:Activated Protein C Resistance / Q000235:genetics; D000925:Anticoagulants / Q000627:therapeutic use; D005165:Factor V / Q000235:genetics; D006710:Homocysteine / Q000097:blood; D006801:Humans; D015233:Models, Statistical; D017354:Point Mutation / Q000235:genetics; D015995:Prevalence; D011516:Prothrombin / Q000235:genetics; D012008:Recurrence; D012307:Risk Factors; D013923:Thromboembolism / Q000097:blood / Q000235:genetics* / Q000517:prevention & control; D020246:Venous Thrombosis / Q000097:blood / Q000235:genetics* / Q000517:prevention & control
D000925:Anticoagulants; C095381:factor V Leiden; D006710:Homocysteine; D005165:Factor V; D011516:Prothrombin